A comparison of five different bone resorption markers in osteosarcoma-bearing dogs, normal dogs, and dogs with orthopedic diseases

Journal of Veterinary Internal Medicine

Volumn 22, Issue 4, 2008, Pages 1008-1013

  Lucas, P W ^a   Fan, Timothy M ^a   Garrett, L D ^a   Griffon, D J ^a   Wypij, J M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Bone pain; Canine cancer; Circulating surrogate markers; Focal malignant osteolysis

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; COMPARATIVE STUDY; DOG; DOG DISEASE; FEMALE; MALE; METABOLISM; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOSARCOMA; URINE;

ANIMALS; BIOLOGICAL MARKERS; BONE RESORPTION; DOG DISEASES; DOGS; FEMALE; MALE; OSTEOARTHRITIS; OSTEOSARCOMA;

ANIMALIA; CANIS FAMILIARIS;

EID: 47849088143     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0134.x     Document Type: Article

References (30)

1. Jilka RL. Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med Pediatr Oncol 2003;41:182-185.
2. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000;88:2919-2926.
3. Camozzi V, Tossi A, Simoni E, et al. Role of biochemical markers of bone remodeling in clinical practice. J Endocrinol Invest 2007;30:13-17.
4. Leeming DJ, Alexandersen P, Karsdal MA, et al. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006;62:781-792.
5. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003;32:83-113 vi-vii.
6. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Clin Orthop Relat Res 2003:S138-S147.
7. Agnello KA, Trumble TN, Chambers JN, et al. Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis. Am J Vet Res 2005;66:1487-1495.
8. Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031-2037.
9. Fan TM, de Lorimier LP, O'Dell-Anderson K, et al. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med 2007;21:431-439.
10. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001;27:187-192; discussion 193-196.
11. Houze P, Bellik B, Brouet JC, et al. Comparison of urinary markers for bone resorption in multiple myeloma. Clin Chim Acta 2000;300:181-193.
12. Lacoste H, Fan TM, de Lorimier LP, et al. Urine N-telopeptide excretion in dogs with appendicular osteosarcoma. J Vet Intern Med 2006;20:335-341.
13. Shankar S, Hosking DJ. Biochemical assessment of Paget's disease of bone. J Bone Miner Res 2006;21(Suppl 2):P22-P27.
14. Takahara K, Kamimura M, Hashidate H, et al. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures. J Orthop Sci 2007;12:219-226.
15. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006;12:3361-3367.
16. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850-856.
17. Veri A, D'Andrea MR, Bonginelli P, et al. Clinical usefulness of bisphosphonates in oncology: Treatment of bone metastases, antitumoral activity and effect on bone resorption markers. Int J Biol Markers 2007;22:24-33.
18. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-2026.
19. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:74-80.
20. Barger A, Graca R, Bailey K, et al. Use of alkaline phosphatase staining to differentiate canine osteosarcoma from other vimentin-positive tumors. Vet Pathol 2005;42:161-165.
21. Britt T, Clifford C, Barger A, et al. Diagnosing appendicular osteosarcoma with ultrasound-guided fine-needle aspiration: 36 cases. J Small Anim Pract 2007;48:145-150.
22. Allen MJ, Allen LC, Hoffmann WE, et al. Urinary markers of type I collagen degradation in the dog. Res Vet Sci 2000;69:123-127.
23. Ladlow JF, Hoffmann WE, Breur GJ, et al. Biological variability in serum and urinary indices of bone formation and resorption in dogs. Calcif Tissue Int 2002;70:186-193.
24. Allen MJ, Hoffmann WE, Richardson DC, et al. Serum markers of bone metabolism in dogs. Am J Vet Res 1998;59:250-254.
25. Ehrhart N, Dernell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 1998;213:1002-1006.
26. Garzotto CK, Berg J, Hoffmann WE, et al. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma, J Vet Intern Med 2000;14:587-592.
27. Ferrari S, Zolezzi C, Pratelli L, et al. Urinary excretion of pyridinium cross-links and serum osteocalcin levels in patients with primary high-grade osteosarcoma. Calcif Tissue Int 2003;73:1-4.
28. Terpos E, Palermos J, Tsionos K, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000;65:331-336.
29. Kim SW, Park DJ, Park KS, et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 2005;52:667-674.
30. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24:237-244.